BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oza J, Doshi SD, Hao L, Musi E, Schwartz GK, Ingham M. Homologous recombination repair deficiency as a therapeutic target in sarcoma. Seminars in Oncology 2020;47:380-9. [DOI: 10.1053/j.seminoncol.2020.10.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Hanvic B, Ray-Coquard I. Gynecological sarcomas: literature review of 2020. Curr Opin Oncol 2021;33:345-50. [PMID: 34009140 DOI: 10.1097/CCO.0000000000000753] [Reference Citation Analysis]
2 Roulleaux Dugage M, Nassif EF, Italiano A, Bahleda R. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. Front Immunol 2021;12:775761. [PMID: 34925348 DOI: 10.3389/fimmu.2021.775761] [Reference Citation Analysis]
3 Tan H, Zuo L, Ma S, Wang D, Li R, Yang Y, Liu W, Chi Y. Efficacy and Safety of Epirubicin Combined with Temozolomide for Treatment of Advanced Leiomyosarcoma. Cancer Manag Res 2021;13:9075-83. [PMID: 34916850 DOI: 10.2147/CMAR.S342213] [Reference Citation Analysis]
4 Cai D, Ma X, Guo H, Zhang H, Bian A, Yu H, Cheng W. Prognostic value of p16, p53, and pcna in sarcoma and an evaluation of immune infiltration. J Orthop Surg Res 2022;17:305. [PMID: 35689249 DOI: 10.1186/s13018-022-03193-3] [Reference Citation Analysis]
5 Kasper B, D'Ambrosio L, Davis EJ, Ingham M, Broto JM, Trent JC, van Houdt WJ, Van Tine BA. What Clinical Trials Are Needed for Treatment of Leiomyosarcoma? Curr Treat Options Oncol 2022. [PMID: 35275323 DOI: 10.1007/s11864-021-00928-y] [Reference Citation Analysis]
6 Pacheco-Barcia V, Muñoz A, Castro E, Ballesteros AI, Marquina G, González-Díaz I, Colomer R, Romero-Laorden N. The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. Cancers (Basel) 2022;14:2950. [PMID: 35740616 DOI: 10.3390/cancers14122950] [Reference Citation Analysis]
7 Ciccarone F, Bruno M, De Paolis E, Piermattei A, De Bonis M, Lorusso D, Zannoni GF, Normanno N, Minucci A, Scambia G, Ferrandina G. Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis. Cancers (Basel) 2022;14:1934. [PMID: 35454841 DOI: 10.3390/cancers14081934] [Reference Citation Analysis]
8 Qi H, Liu Y, Wu L, Liu C, Ni S, Liu Q, Ni X, Sun Q. Mg-HA-C/C Composites Promote Osteogenic Differentiation and Repair Bone Defects Through Inhibiting miR-16. Front Bioeng Biotechnol 2022;10:838842. [DOI: 10.3389/fbioe.2022.838842] [Reference Citation Analysis]
9 Lin H, Xie Y, Kong Y, Yang L, Li M. Identification of molecular subtypes and prognostic signature for hepatocellular carcinoma based on genes associated with homologous recombination deficiency. Sci Rep 2021;11:24022. [PMID: 34912005 DOI: 10.1038/s41598-021-03432-3] [Reference Citation Analysis]
10 Seligson ND, Tang J, Jin DX, Bennett MP, Elvin JA, Graim K, Hays JL, Millis SZ, Miles WO, Chen JL. Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas. NPJ Precis Oncol 2022;6:29. [PMID: 35468996 DOI: 10.1038/s41698-022-00271-x] [Reference Citation Analysis]